Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders
Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders
复制标题
DOI：
10.1136/jnnp.70.4.538
复制
发表时间：
2001-04-01
影响因子：
11
通讯作者：
Vaj, P
中科院分区：
文献类型：
--
作者：
Porta, M;Gamba, M;Vaj, P
目的：探讨超声引导下涎腺注射A型肉毒毒素(BTX-A)治疗神经性疾病患者涎带的安全性和有效性。方法10例患者在超声引导下腮腺和颌下腺注射BTX-A。在注射前，使用视觉模拟评分评估流涎的基线比率。注射后，定期重复评估长达一年。结果-在接受治疗的10名患者中，9名(90%)报告治疗后主观上唾液减少，1名患者(10%)没有改善。视觉模拟评分显示，所有患者的平均流涎率下降了55%，应答组下降了60.8%。结论：这是首次报道(1)腮腺和颌下腺同时注射BTX-A(BO-TOX(R))，以及(2)在BTX-A注射到唾液腺期间使用超声引导。结果表明，该技术是安全的，BTX-A注射治疗神经系统疾病患者的唾液是有效的。
Objectives-To investigate the safety and efficacy of ultrasound guided botulinum toxin type A (BTX-A) injections into salivary glands for the treatment of sialorrhoea in patients with neurological disorders.Methods-The parotid and submandibular glands of 10 patients were injected with BTX-A using ultrasound guidance. Before injection, the baseline rate of salivation was assessed using a visual analogue scale. Postinjection, assessments were repeated at regular intervals for up to 1 year.Results-Of the 10 patients treated, nine (90%) reported a subjective reduction in salivation post-treatment and one patient (10%) found no improvement. Visual analogue scale scores showed a reduction of 55% in the mean rate of salivation for all patients and a reduction of 60.8% for the group of responders. No serious adverse events occurred and no procedure related complications were reported.Conclusions-This is the first study to report (1) the injection of BTX-A (BO-TOX(R)) into both parotid and submandibular glands, and (2) the use of ultrasound guidance during the administration of BTX-A into salivary glands. The results suggest that the technique is safe and that BTX-A injections are effective for the treatment of sialorrhoea in patients with neurological disorders.